tradingkey.logo

Palvella Therapeutics Provides Corporate Update And 2026 Outlook

ReutersJan 9, 2026 12:55 PM

- Palvella Therapeutics Inc PVLA.O:

  • PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIES

  • PALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026

  • PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026

  • PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026

  • PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI